Kronox Lab Sciences Q3FY26 Standalone Revenue at ₹2,527.40 Lakhs
Kronox Lab Sciences reported standalone un-audited financial results for the quarter ended December 31, 2025. Revenue from operations was ₹2,527.40 Lakhs, and Profit After Tax was ₹658.90 Lakhs. For the nine months ended December 31, 2025, revenue was ₹7,509.37 Lakhs, with Profit After Tax at ₹1,965.79 Lakhs.
The announcement provides quarterly financial results, which are material information for investors. The reported figures, while not showing significant growth or decline, provide an update on the company's financial performance.
The financial results show a slight increase in revenue for the quarter compared to the previous year, but a decrease in profit for the quarter. The nine-month figures also show a modest increase in revenue and profit. Overall, the results are mixed, warranting a neutral sentiment.
Kronox Lab Sciences Limited announced the outcome of its Board Meeting held on Saturday, 14th February, 2026. The Board considered and approved the standalone un-audited financial results for the quarter and nine months ended 31st December, 2025, along with the Independent Auditors’ Limited Review Report.
The financial results for the quarter ended 31st December, 2025, show a revenue from operations of ₹2,527.40 Lakhs, compared to ₹2,401.11 Lakhs in the same quarter of the previous year. Total income for the quarter stood at ₹2,640.65 Lakhs. Expenses for the quarter were ₹1,780.85 Lakhs, leading to a Profit Before Tax of ₹859.80 Lakhs. The Profit After Tax for the period was ₹658.90 Lakhs.
For the nine months ended 31st December, 2025, the revenue from operations was ₹7,509.37 Lakhs, and the Profit After Tax was ₹1,965.79 Lakhs. The total comprehensive income for the nine-month period was ₹1,979.47 Lakhs. The Board Meeting commenced at 2:00 p.m. and concluded at 2:30 p.m.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.